
Merck (MRK) Stock Forecast & Price Target
Merck (MRK) Analyst Ratings
Bulls say
Merck & Co is a global biopharmaceutical company that operates in two primary segments: Merck Pharmaceutical which focuses on research-based biopharmaceutical products and Merck Manufacturing which provides contract manufacturing and animal health products. The company has a positive outlook because of its diverse portfolio of products, including Keytruda, which is a major contributor to overall sales in the immuno-oncology market. Additionally, the company has a substantial vaccines business and is continuously investing in research and development to expand its pipeline and bring new products to market. Recent and upcoming milestones in the pipeline, such as data from Phase 3 trials for sac-TMT and potential approvals for enlicitide and Winrevair, have the potential to drive future revenue growth. However, the recent acquisition of Terns Pharma and potential patent losses for Keytruda may have a negative impact on earnings in the short term.
Bears say
Merck & Co is likely to face declining sales and margins due to the expiration of key patents for blockbuster drugs and potential challenges from generic and biosimilar companies. Positive pipeline data and potential approval of new drugs may provide a brief boost, but the company faces significant competition in various therapeutic areas. Additionally, macroeconomic conditions and a potential shift away from defensive stocks could impact Merck's stock price.
This aggregate rating is based on analysts' research of Merck and is not a guaranteed prediction by Public.com or investment advice.
Merck (MRK) Analyst Forecast & Price Prediction
Start investing in Merck (MRK)
Order type
Buy in
Order amount
Est. shares
0 shares